Meeting
2022 ASCO Annual Meeting
Clinical utility of tumor next-generational sequencing (NGS) panel testing to inform treatment decisions for patients with advanced solid tumors.
Authors
Lucia Bogdan
Department of Internal Medicine, University of Toronto, Toronto, ON, Canada
Lucia Bogdan , Ramy R. Saleh , Lisa Avery , Samanta Del Rossi , Celeste Yu , Philippe L. Bedard
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Tissue-Based Biomarkers
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 3119)
DOI
10.1200/JCO.2022.40.16_suppl.3119
Abstract #
3119
Poster Bd #
111
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Return of results after somatic tumor mutation profiling in advanced cancer: Psychological impacts.
First Author: Phyllis Butow
Poster
2014 ASCO Annual Meeting
Effect of clinical NGS-based cancer genomic profiling on physician treatment decisions in advanced solid tumors.
First Author: Fadi S. Braiteh
Poster
2022 ASCO Annual Meeting
Dual tissue and plasma testing to improve detection of actionable variants in patients with solid cancers.
First Author: Matthew Mackay